April 25, 2008Stroke

Temporary Pretreatment With the Angiotensin II Type 1 Receptor Blocker, Valsartan, Prevents Ischemic Brain Damage Through an Increase in Capillary Density

View Full Paper

Ask AI

Bookmark

Why the study?

Does temporary pretreatment with valsartan reduce ischemic brain damage in a mouse model of middle cerebral artery occlusion?

Structured PICO

Does temporary pretreatment with valsartan reduce ischemic brain damage in a mouse model of middle cerebral artery occlusion?

Population

C57BL/6 mice subjected to middle cerebral artery (MCA) occlusion

Intervention

Valsartan (nonhypotensive dose) pretreatment for 4 weeks, or for 2 weeks followed by 2 weeks cessation

Comparator

No treatment for 4 weeks before MCA occlusion

Outcome

Ischemic volume, DNA damage, superoxide production, and mRNA levels of monocyte chemoattractant protein-1 and tumor necrosis factor-alpha on the ipsilateral side after 24 hours of MCA occlusionsurrogate

Temporary pretreatment with valsartan protects against ischemic brain damage in mice, likely through increased capillary density.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Should not change clinical practice; hypothesis-generating for ARB pretreatment in human stroke prevention.

Cite This Study

Li et al. (2008) studied this question.

synapsesocial.com/papers/6a83a79ad65172829ee65521 https://doi.org/10.1161/strokeaha.107.503458

View Full Paper

Ask AI

Bookmark

Temporary Pretreatment With the Angiotensin II Type 1 Receptor Blocker, Valsartan, Prevents Ischemic Brain Damage Through an Increase in Capillary Density

Structured PICO

Discussion

Implication

Cite This Study

Temporary Pretreatment With the Angiotensin II Type 1 Receptor Blocker, Valsartan, Prevents Ischemic Brain Damage Through an Increase in Capillary Density

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider